Posts tagged Vital board
Vital Therapies updates Phase 3 trial

In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company's Phase 3 trial, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.  

There are now 24 sites open for enrollment in the U.S and EU. The company expects to announce topline results in mid-2018.

Read More